Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 May 2019 | Story Ruan Bruwer | Photo Varsity Sports
Lefébre Rademan
Lefébre Rademan, new captain of the Free State Crinums netball team, could be one of the star players in the Premier League. She is a fifth-year Education student.

The Free State Crinums netball team, a de facto Kovsie team with all 15 squad members enrolled for courses at the University of the Free State (UFS), will draw inspiration from their success in last year’s Varsity netball tournament. The Kovsies won the student competition for a record third time. 

During the weekend of 10 May 2019, the Crinums will play their first match in the 2019 Premier League. They lost a couple of key players in captain Alicia Puren, Protea Khanyisa Chawane, (both playing for the national invitational team in the league), Khomotso Mamburu (moved to Cape Town), and Meagan Roux (injured). They do, however, still have the services of players such as Tanya von Berg (playing in her sixth Premier League, one of only a handful of players to do so), Lefébre Rademan, Sikholiwe Mdletshe, Ané Retief, Gertriana Retief, and Rieze Straeuli. Rademan is the new captain and was one of the standout players in last year’s Varsity netball, earning three Player of the Match awards, including the Player of the Final. 

The team will again be coached by Burta de Kock, who is also the head coach of the Kovsies. Under her leadership, the Crinums won the Premier League for the first three years (2014 to 2016). Last year, the Crinums ended fourth. De Kock will be assisted by Martha Mosoahle-Samm. She is a former Protea assistant coach who also captained South Africa and played for the UFS between 1997 and 1999.

There are four first-year students in the squad of 15 players: Oageng Khasake (wing attack), Ancia Pienaar (goalkeeper), Rolene Streutker (goal shooter), Boitumelo Mahloko (goal defence). Pienaar and Mahloko both represented South Africa at junior level in 2018.

■ Crinums squad: Ané Retief, Gertriana Retief, Jana Scholtz, Lefébre Rademan, Sikholiwe Mdletshe, Tanya von Berg, Rieze Straeuli, Claudia van den Berg, Zandré Smit, Oageng Khasake, Bianca de Wee, Ancia Pienaar, Rolene Streutker, Chanel Vrey, Boitumelo Mahloko.


News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept